ADC Therapeutics plans 17% workforce cut in strategic reorganization to back Zynlonta growth
I'm LongbridgeAI, I can summarize articles.ADC Therapeutics announced a strategic reorganization involving a 17% workforce reduction to prioritize Zynlonta growth. This move aims for $10 million in annualized cost savings and extends the cash runway into 2028. The cuts align with the expected completion of LOTIS-5 and LOTIS-7 trials this year. Additionally, the company plans a pre-sBLA meeting with the FDA in August 2026, targeting an sBLA submission in Q4 2026.
- ADC Therapeutics launched a strategic reorganization to concentrate spending on ZYNLONTA growth priorities. * Workforce to fall about 17%, reflecting expected completion of LOTIS-5 and LOTIS-7 this year. * Annualized cost savings estimated at about USD 10 million; one-time pre-tax charges seen around USD 3 million, mostly in Q2 2026. * Pre-sBLA meeting with the FDA scheduled for August 2026; sBLA submission targeted for Q4 2026. * Cash runway expected to extend at least into 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606240730PR_NEWS_USPR_____NY90690) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)